These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37436640)

  • 1. Role of Circulating Tumor DNA Among Patients with Colorectal Peritoneal Metastases.
    Baumgartner JM; Botta GP
    J Gastrointest Cancer; 2024 Mar; 55(1):41-46. PubMed ID: 37436640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer.
    Bansal VV; Belmont E; Godley F; Dhiman A; Witmer HD; Li S; Liao A; Eng OS; Turaga KK; Shergill A
    J Am Coll Surg; 2024 Jun; 238(6):1013-1020. PubMed ID: 38299640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
    Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ
    J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 5. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    Parikh AR; Chee BH; Tsai J; Rich TA; Price KS; Patel SA; Zhang L; Ibrahim F; Esquivel M; Van Seventer EE; Jarnagin JX; Raymond VM; Corvera CU; Hirose K; Nakakura EK; Corcoran RB; Van Loon K; Atreya CE
    Clin Cancer Res; 2024 Jul; 30(14):2964-2973. PubMed ID: 38695832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of ctDNA in colorectal cancer with peritoneal metastases.
    Xue J; Prabhakaran S; Prabhakaran S; Lim WM; Guerra G; Heriot A; Kong JC
    ANZ J Surg; 2023 Mar; 93(3):506-509. PubMed ID: 36200726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Tumor-informed Personalized Circulating Tumor DNA Assay in Informing Recurrence in Patients With Peritoneal Metastases From Colorectal and High-grade Appendix Cancer Undergoing Curative-intent Surgery.
    Dhiman A; Kothary V; Witmer HDD; Bregio C; Sood D; Ong CT; Polite B; Eng OS; Shergill A; Turaga KK
    Ann Surg; 2023 Dec; 278(6):925-931. PubMed ID: 36994703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer.
    Adams AM; Vreeland TJ; Newhook TE
    J Gastrointest Cancer; 2023 Dec; 54(4):1071-1081. PubMed ID: 36562938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.
    Baumgartner JM; Raymond VM; Lanman RB; Tran L; Kelly KJ; Lowy AM; Kurzrock R
    Ann Surg Oncol; 2018 Aug; 25(8):2400-2408. PubMed ID: 29948422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
    Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer.
    Symonds EL; Pedersen SK; Murray D; Byrne SE; Roy A; Karapetis C; Hollington P; Rabbitt P; Jones FS; LaPointe L; Segelov E; Young GP
    Cancer; 2020 Apr; 126(7):1460-1469. PubMed ID: 31909823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
    Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
    World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases.
    Baumgartner JM; Riviere P; Lanman RB; Kelly KJ; Veerapong J; Lowy AM; Kurzrock R
    Ann Surg Oncol; 2020 Sep; 27(9):3259-3267. PubMed ID: 32767050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
    Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study.
    Li Y; Xu J; Hu X; Chen Y; Liu F; Chen Y; Ma X; Dong Q; Sun L; Mo S; Zhang L; He X; Tong S; Wu H; Li W; Cai S; Zhu S; Pan Q; Peng J
    Int J Surg; 2024 May; 110(5):2776-2787. PubMed ID: 38445460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations.
    Wong R; Tie J; Lee M; Cohen J; Wang Y; Li L; Ma S; Christie M; Kosmider S; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Int J Cancer; 2019 Jul; 145(2):540-547. PubMed ID: 30628066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
    Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
    Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort.
    Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL
    Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumour DNA, a promising biomarker for the management of colorectal cancer.
    Khakoo S; Georgiou A; Gerlinger M; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2018 Feb; 122():72-82. PubMed ID: 29458792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.